Once gemcitabine enters the tumor cell, it is phosphorylated by deoxycytidine kinase (DCK) as a first step towards its active and cytotoxic form difluorodeoxycytidine triphosphate (dFdCTP). This evidence concerns the gene DCK and neoplasm.